175 related articles for article (PubMed ID: 37173186)
1. Ferroptosis vulnerability in FLT3-mutant leukemia.
Lee H; Zhuang L; Gan B
Trends Cancer; 2023 Jul; 9(7):524-525. PubMed ID: 37173186
[TBL] [Abstract][Full Text] [Related]
2. C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier M; Birsen R; Lauture L; Mouche S; Angelino P; Dehairs J; Goupille L; Boussaid I; Heiblig M; Boet E; Sahal A; Saland E; Santos JC; Armengol M; Fernández-Serrano M; Farge T; Cognet G; Simonetta F; Pignon C; Graffeuil A; Mazzotti C; Avet-Loiseau H; Delos O; Bertrand-Michel J; Chedru A; Dembitz V; Gallipoli P; Anstee NS; Loo S; Wei AH; Carroll M; Goubard A; Castellano R; Collette Y; Vergez F; Mansat-De Mas V; Bertoli S; Tavitian S; Picard M; Récher C; Bourges-Abella N; Granat F; Kosmider O; Sujobert P; Colsch B; Joffre C; Stuani L; Swinnen JV; Guillou H; Roué G; Hakim N; Dejean AS; Tsantoulis P; Larrue C; Bouscary D; Tamburini J; Sarry JE
Cancer Discov; 2023 Jul; 13(7):1720-1747. PubMed ID: 37012202
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance in mutant FLT3-positive AML.
Weisberg E; Sattler M; Ray A; Griffin JD
Oncogene; 2010 Sep; 29(37):5120-34. PubMed ID: 20622902
[TBL] [Abstract][Full Text] [Related]
4. FLT3 Inhibition in Acute Myeloid Leukemia.
Smith CC
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
[TBL] [Abstract][Full Text] [Related]
5. A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.
Long J; Chen X; Shen Y; Lei Y; Mu L; Wang Z; Xiang R; Gao W; Wang L; Wang L; Jiang J; Zhang W; Lu H; Dong Y; Ding Y; Zhu H; Hong D; Sun YE; Hu J; Liang A
Cell Rep Med; 2023 Nov; 4(11):101286. PubMed ID: 37951217
[TBL] [Abstract][Full Text] [Related]
6. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H; Kawashima N; Ishikawa Y
Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
[TBL] [Abstract][Full Text] [Related]
7. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
Yen SC; Chen LC; Huang HL; Ngo ST; Wu YW; Lin TE; Sung TY; Lien ST; Tseng HJ; Pan SL; Huang WJ; Hsu KC
J Nat Prod; 2021 Jan; 84(1):1-10. PubMed ID: 33393294
[TBL] [Abstract][Full Text] [Related]
8. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
9. Will newer tyrosine kinase inhibitors have an impact in AML?
Levis MJ
Best Pract Res Clin Haematol; 2010 Dec; 23(4):489-94. PubMed ID: 21130412
[TBL] [Abstract][Full Text] [Related]
10. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
11. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella A; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Expert Opin Emerg Drugs; 2022 Mar; 27(1):1-18. PubMed ID: 35076348
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
15. Fms -like tyrosine kinase 3 positive acute myeloid leukemia.
Isidori A; Visani G; Ferrara F
Curr Opin Oncol; 2023 Nov; 35(6):589-593. PubMed ID: 37820093
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
[TBL] [Abstract][Full Text] [Related]
17. [Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].
Najima Y
Rinsho Ketsueki; 2023; 64(9):932-941. PubMed ID: 37793868
[TBL] [Abstract][Full Text] [Related]
18. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
Eisfelder BJ; Saygin C; Wynne J; Colton MW; Fischietti M; Beauchamp EM; Cheng JX; Odenike O; Roboz G; Alachkar H; Stock W
Blood Cancer J; 2021 Mar; 11(3):48. PubMed ID: 33658483
[TBL] [Abstract][Full Text] [Related]
19. The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.
He S; Zhang M; Li J; Zhao W; Yu L; Han Y; Pang Y
J Int Med Res; 2022 May; 50(5):3000605221097774. PubMed ID: 35549749
[TBL] [Abstract][Full Text] [Related]
20. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
